Financial Ratios Mesa Laboratories, Inc.
Stocks
MLAB
US59064R1095
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.94 USD | -1.51% |
|
+2.44% | +24.76% |
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 1.28 | 0.3 | 0.42 | 2.5 | 2.69 | |||||
Return on Total Capital | 1.43 | 0.34 | 0.48 | 3.01 | 3.26 | |||||
Return On Equity % | 0.47 | 0.24 | -94.36 | -1.29 | 3.88 | |||||
Return on Common Equity | 0.47 | 0.24 | -94.36 | -1.29 | 3.88 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 63.23 | 61.02 | 62.2 | 63.12 | 63.53 | |||||
SG&A Margin | 47.4 | 50.16 | 51.57 | 47.73 | 47.95 | |||||
EBITDA Margin % | 20.87 | 16.95 | 16.31 | 17.47 | 16.77 | |||||
EBITA Margin % | 19.1 | 14.67 | 14.35 | 15.24 | 14.66 | |||||
EBIT Margin % | 7.27 | 1.52 | 1.71 | 7.29 | 7.43 | |||||
Income From Continuing Operations Margin % | 1.01 | 0.42 | -117.6 | -0.82 | 2.69 | |||||
Net Income Margin % | 1.01 | 0.42 | -117.6 | -0.82 | 2.69 | |||||
Net Avail. For Common Margin % | 1.01 | 0.42 | -117.6 | -0.82 | 2.69 | |||||
Normalized Net Income Margin | 4.16 | -0.11 | 0.03 | 1.12 | 3.01 | |||||
Levered Free Cash Flow Margin | 9.02 | 11.42 | 21.02 | 25.08 | 12.8 | |||||
Unlevered Free Cash Flow Margin | 10.33 | 12.78 | 22.67 | 28.15 | 15.48 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.28 | 0.32 | 0.39 | 0.55 | 0.58 | |||||
Fixed Assets Turnover | 5.89 | 5.79 | 5.52 | 5.35 | 5.15 | |||||
Receivables Turnover (Average Receivables) | 5.67 | 5.23 | 5.3 | 5.95 | 5.79 | |||||
Inventory Turnover (Average Inventory) | 3.79 | 2.88 | 2.43 | 3.06 | 3.51 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.59 | 2.74 | 2.47 | 0.63 | 1.72 | |||||
Quick Ratio | 1.88 | 1.74 | 1.52 | 0.43 | 1.17 | |||||
Operating Cash Flow to Current Liabilities | 0.82 | 0.65 | 1 | 0.29 | 0.69 | |||||
Days Sales Outstanding (Average Receivables) | 64.36 | 69.79 | 69.08 | 61.36 | 63.05 | |||||
Days Outstanding Inventory (Average Inventory) | 96.35 | 126.63 | 150.77 | 119.18 | 103.92 | |||||
Average Days Payable Outstanding | 27.8 | 26.83 | 27.94 | 26.37 | 21.21 | |||||
Cash Conversion Cycle (Average Days) | 132.91 | 169.58 | 191.91 | 154.17 | 145.76 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 58.04 | 48.77 | 159.08 | 121.29 | 90.65 | |||||
Total Debt / Total Capital | 36.73 | 32.78 | 61.4 | 54.81 | 47.55 | |||||
LT Debt/Equity | 57.34 | 48.04 | 157.03 | 55.86 | 85.65 | |||||
Long-Term Debt / Total Capital | 36.28 | 32.29 | 60.61 | 25.24 | 44.93 | |||||
Total Liabilities / Total Assets | 44.33 | 40.55 | 67.46 | 63.12 | 56.46 | |||||
EBIT / Interest Expense | 3.45 | 0.7 | 0.65 | 1.48 | 1.73 | |||||
EBITDA / Interest Expense | 10.52 | 8.58 | 6.89 | 4.05 | 4.58 | |||||
(EBITDA - Capex) / Interest Expense | 9.38 | 7.62 | 6.44 | 3.69 | 4.27 | |||||
Total Debt / EBITDA | 5.59 | 4.69 | 5.89 | 4.04 | 3.45 | |||||
Net Debt / EBITDA | 4.39 | 3.89 | 5.17 | 3.43 | 2.87 | |||||
Total Debt / (EBITDA - Capex) | 6.27 | 5.28 | 6.31 | 4.43 | 3.7 | |||||
Net Debt / (EBITDA - Capex) | 4.92 | 4.37 | 5.54 | 3.77 | 3.07 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 37.63 | 18.85 | -1.32 | 11.47 | 3.38 | |||||
Gross Profit, 1 Yr. Growth % | 33.95 | 14.71 | 0.59 | 13.1 | 4.06 | |||||
EBITDA, 1 Yr. Growth % | 28.18 | -0.24 | -3.27 | 19.38 | -0.74 | |||||
EBITA, 1 Yr. Growth % | 31.05 | -5.38 | -3.46 | 18.32 | -0.5 | |||||
EBIT, 1 Yr. Growth % | 8.5 | -72.71 | 11.05 | 376.48 | 5.37 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -42.85 | -50.29 | -27.44K | -99.22 | -440.02 | |||||
Net Income, 1 Yr. Growth % | -42.85 | -50.29 | -27.44K | -99.22 | -440.02 | |||||
Normalized Net Income, 1 Yr. Growth % | 433.22 | -103.52 | -129.31 | 3.68K | 179.01 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -45.31 | -51.43 | -27.87K | -99.23 | -432.29 | |||||
Accounts Receivable, 1 Yr. Growth % | 73.3 | 3.22 | -8.22 | 7.46 | 5.07 | |||||
Inventory, 1 Yr. Growth % | 120.13 | 40.79 | -5.68 | -22.37 | 3.97 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 63.12 | -5.1 | 12.47 | 17.56 | -1.24 | |||||
Total Assets, 1 Yr. Growth % | 17.61 | -6.44 | -32.49 | -3.01 | -1.29 | |||||
Tangible Book Value, 1 Yr. Growth % | -210.35 | -25.56 | 35.23 | -19.97 | -29.33 | |||||
Common Equity, 1 Yr. Growth % | -3.06 | -0.08 | -63.05 | 9.93 | 16.53 | |||||
Cash From Operations, 1 Yr. Growth % | 5.8 | -28.66 | 57.71 | 6.06 | -8.5 | |||||
Capital Expenditures, 1 Yr. Growth % | 122.49 | 2.53 | -43.51 | 65.52 | -23.51 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -53.61 | 57.97 | 86.78 | 27.64 | -47.24 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -53.36 | 53.29 | 79.43 | 33.27 | -43.15 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 0 | 0 | 0 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 25.15 | 27.89 | 8.3 | 4.88 | 7.35 | |||||
Gross Profit, 2 Yr. CAGR % | 33.54 | 23.95 | 11.03 | 6.66 | 8.49 | |||||
EBITDA, 2 Yr. CAGR % | 35.64 | 11.24 | 8.83 | 7.46 | 8.85 | |||||
EBITA, 2 Yr. CAGR % | 37.74 | 9.37 | 8.19 | 6.88 | 8.5 | |||||
EBIT, 2 Yr. CAGR % | 30.09 | -48.17 | -11.45 | 130.03 | 124.07 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 2.58 | -46.7 | 1.07K | 45.69 | -83.75 | |||||
Net Income, 2 Yr. CAGR % | 2.58 | -46.7 | 1.07K | 45.69 | -83.75 | |||||
Normalized Net Income, 2 Yr. CAGR % | 78.32 | -58.9 | -82.14 | 232.71 | 926.58 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -7.61 | -48.46 | 1.06K | 46.36 | -83.99 | |||||
Accounts Receivable, 2 Yr. CAGR % | 39.67 | 33.75 | -2.67 | -0.69 | 6.26 | |||||
Inventory, 2 Yr. CAGR % | 31.5 | 76.04 | 15.24 | -14.43 | -10.16 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 25.76 | 24.42 | 3.31 | 14.99 | 7.75 | |||||
Total Assets, 2 Yr. CAGR % | 31.49 | 4.9 | -20.52 | -19.08 | -2.16 | |||||
Tangible Book Value, 2 Yr. CAGR % | 88.76 | -9.37 | 0.33 | 4.03 | -24.79 | |||||
Common Equity, 2 Yr. CAGR % | 33.79 | -1.58 | -39.24 | -36.27 | 13.18 | |||||
Cash From Operations, 2 Yr. CAGR % | 20.55 | -13.12 | 6.07 | 29.33 | -1.49 | |||||
Capital Expenditures, 2 Yr. CAGR % | 72.01 | 51.03 | -23.9 | -3.3 | 12.52 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 105.58 | -16.42 | 101.65 | 57.59 | -17.94 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 60.74 | -17.19 | 89.8 | 57.6 | -12.96 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 0 | 0 | 0 | 0 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 21.36 | 23.02 | 17.3 | 9.34 | 4.38 | |||||
Gross Profit, 3 Yr. CAGR % | 24.15 | 26.94 | 15.62 | 11.72 | 5.79 | |||||
EBITDA, 3 Yr. CAGR % | 12.14 | 21.1 | 5.51 | 12.24 | 4.65 | |||||
EBITA, 3 Yr. CAGR % | 12.18 | 20.09 | 4.91 | 11.47 | 4.36 | |||||
EBIT, 3 Yr. CAGR % | -9.11 | -25.17 | -33.18 | 55.17 | 77.32 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -37 | -19.43 | 326.64 | 1.8 | 93.25 | |||||
Net Income, 3 Yr. CAGR % | -37 | -19.43 | 326.64 | 1.8 | 93.25 | |||||
Normalized Net Income, 3 Yr. CAGR % | -9.73 | -53.47 | -63.28 | 6.41 | 213.75 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -42.7 | -25.43 | 319.38 | 1.33 | 92.36 | |||||
Accounts Receivable, 3 Yr. CAGR % | 48.79 | 26.28 | 17.97 | 0.6 | 1.2 | |||||
Inventory, 3 Yr. CAGR % | 53.74 | 34.52 | 42.98 | 1.02 | -8.69 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 20.43 | 14.5 | 20.3 | 7.86 | 9.3 | |||||
Total Assets, 3 Yr. CAGR % | 65.25 | 17.39 | -9.43 | -15.07 | -13.54 | |||||
Tangible Book Value, 3 Yr. CAGR % | 132.63 | 38.42 | 3.57 | -6.95 | -8.55 | |||||
Common Equity, 3 Yr. CAGR % | 52.37 | 21.38 | -29 | -25.96 | -22.07 | |||||
Cash From Operations, 3 Yr. CAGR % | 8.68 | 1.21 | 5.98 | 6.07 | 15.24 | |||||
Capital Expenditures, 3 Yr. CAGR % | 52 | 44.76 | 8.82 | -1.4 | -10.57 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -19.11 | 85.32 | 8.26 | 75.52 | 9.43 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -16.31 | 56.03 | 6.27 | 70.85 | 12.19 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 0 | 0 | 0 | 0 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 14.5 | 17.9 | 15.95 | 15.41 | 13.22 | |||||
Gross Profit, 5 Yr. CAGR % | 16.67 | 19.61 | 17.16 | 18.4 | 12.71 | |||||
EBITDA, 5 Yr. CAGR % | 8.38 | 7.84 | 5.26 | 15.02 | 6.84 | |||||
EBITA, 5 Yr. CAGR % | 8.48 | 6.99 | 4.46 | 14.62 | 6.33 | |||||
EBIT, 5 Yr. CAGR % | -4.63 | -26.99 | -27.06 | 17.26 | 8.42 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -30.06 | -20.68 | 102.41 | 2.11 | 15.44 | |||||
Net Income, 5 Yr. CAGR % | -30.06 | -20.68 | 102.41 | 2.11 | 15.44 | |||||
Normalized Net Income, 5 Yr. CAGR % | -3.89 | -51.24 | -63.12 | 2.2 | 39.15 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -34.53 | -26.45 | 90.94 | -2.34 | 13.58 | |||||
Accounts Receivable, 5 Yr. CAGR % | 23.55 | 24.37 | 25.56 | 14.71 | 13.14 | |||||
Inventory, 5 Yr. CAGR % | 12.14 | 30.29 | 36.99 | 12.26 | 18.73 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 8.35 | 9.32 | 13.27 | 14.69 | 15.12 | |||||
Total Assets, 5 Yr. CAGR % | 32.73 | 32.17 | 23.3 | 1.16 | -6.59 | |||||
Tangible Book Value, 5 Yr. CAGR % | 64.82 | 64.8 | 66.18 | 23.48 | -8.88 | |||||
Common Equity, 5 Yr. CAGR % | 32.12 | 31.69 | 5.49 | -6.19 | -14.44 | |||||
Cash From Operations, 5 Yr. CAGR % | 17.78 | 1.7 | 7.63 | 11.64 | 2.93 | |||||
Capital Expenditures, 5 Yr. CAGR % | -17.51 | 10.18 | 15.26 | 23.18 | 10.29 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 26.35 | 3.71 | 7.68 | 72.72 | -2.3 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 29.84 | 4.93 | 8.57 | 55.88 | -1.14 | |||||
Dividend Per Share, 5 Yr. CAGR % | 0 | 0 | 0 | 0 | 0 |
- Stock Market
- Stocks
- MLAB Stock
- Financials Mesa Laboratories, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















